摘要
目的:比较紫杉醇(泰素)及多西他赛加顺铂方案对Ⅲ_B期非小细胞肺癌的疗效和毒副反应。方法:选取初治Ⅲ_B期非小细胞肺癌45例,分别应用紫杉醇加顺铂、多西他赛加顺铂方案化疗,观察化疗毒副反应,2周期后评价疗效。结果:43例可评价疗效,两组的近期有效率分别为42·3%和52·9%,无显著性差异(χ2=0·467,P=0·494)。二组间Ⅲ、Ⅳ度毒副反应均以骨髓抑制和消化道反应为主,其发生率无统计学差异(P>0·05)。泰素组无严重体液潴留及化疗相关性死亡病例,但多西他赛组有4例患者出现严重体液潴留,其中2例死亡。结论:两方案的近期疗效和主要毒副反应相似,但多西他赛可致体液潴留,应用多西他赛时需强调化疗前的激素足量、化疗后的病情监测和发生体液潴留时的积极处理。。
Objective：To estimate the efficacy, toxicity and side effects of combined chemotherapy of paclitaxel or docetaxel plus cisplatin the treatment of non-small cell lung cancer（NSCLC） with stage ⅢB- Methods ：45 untreated patients with ⅢB NSCLC diagnosed by pathology or cytology were enrolled into two groups. The TP group with 26 patients received paclitaxel plus cisplatin, and the DP group with another 19 patients received docetaxel plus cisplatin. Both regimens had 21-day cycle, i. e. , three weeks repeated and the side effects were evaluated. The efficacy was estimated after 2 cycles of chemotherapy. Results ： The efficacy could be estimated in 43 patients, the overall response rate （ CR ＋ PR） was 42. 2% in the TP group and 52. 9% in the DP group respectively, there was no significant statistical difference （X^2=0. 467 P=0. 494 ）. The major grade Ⅲ and Ⅳ toxicities of two groups were myelosuppression and gastrointestinal reactions and no significant difference appeared （ P 〉 0. 05 ）. There was no chemotherapy-related death and severe fluidd retention in TP group, while in the DP group, 4 patients with severe fluid retention were found and 2 of them were died. Conclusion：The efficacy and major toxicity in two groups are similar, but docetaxel may lead to fluid retention. In order to decrease the fluid retention, sufficient decaderm, careful observation and positive treatment should be emphasized.
出处
《临床肿瘤学杂志》
CAS
2005年第6期649-651,共3页
Chinese Clinical Oncology
关键词
非小细胞肺癌
紫杉醇
多西他赛
顺铂
联合化疗
Non-small cell lung cancer
Paclitaxel
Docetaxel
Cisplatin
Combined chemotherapy
